PSY Shortwave Life Sciences Plc

TIDMPSY

RNS Number : 4899D

Psych Capital PLC

22 June 2023

22 June 2023

PSYCH CAPITAL PLC

("Psych Capital" or "the Company")

PSYCH Symposium 2023: Unlocking the potential of psychedelic medicine on 6(th) July 2023

Europe's leading event in psychedelic medicine, PSYCH Symposium, returns on Thursday 6(th) July 2023 at The British Museum in London

Discover emerging research, technologies and opportunities which have the potential to reshape the landscape of mental health care

Secure your tickets now - click here

Building on the success of last year's inaugural event, PSYCH Symposium 2022, which completely sold out, PSYCH Symposium 2023 will feature an even more action-packed agenda, with speeches and panel discussions from industry leading figures. This year's event aims to facilitate invaluable discussions and connections between industry, government, investors, academia, advocacy groups, patients and beyond, to expedite the development and adoption of this new frontier of medicine, psychedelics.

With record numbers of companies and clinical trials in the psychedelic space, it is clear that the industry is at an inflection point in its journey of bringing these potentially life-changing treatments to patients who desperately need them. To fully realise the potential of this revolutionary area of medicine, all parties need to come together as the industry advances towards approval and commercialisation. PSYCH Symposium proudly aims to do exactly that.

Stephen Murphy, Founder of PSYCH Symposium, commented: "Psychedelic medicine has the potential to revolutionise the treatment of mental health and neurological conditions, fundamentally shifting the way we treat and manage some of the most impactful illnesses affecting modern society today. Last year's PSYCH Symposium surpassed even our greatest expectations and reaffirmed the global interest in this ground-breaking industry. This year we are aiming to go even further and facilitate these crucial discussions which are pivotal in ensuring the psychedelic sector thrives. London represents the natural place for this event to take place, as the capital of the psychedelic cluster which has emerged from its renaissance. We look forward to seeing everyone on Thursday 6(th) July for what promises to be another landmark event."

Covering topics from funding and finance; the future of psychedelic care; and n euroimaging and psychedelics, this year's agenda features an even more exciting line up including:

-- Professor Robin Carhart-Harris: Head Of The Centre For Psychedelic Research, Imperial College London

-- Professor Celia Morgan: Head Of Ketamine Assisted Psychotherapy For Addiction, Awakn Life Sciences

   --    Christian Angermayer: Founder, Apeiron Investment Group 
   --    Sarah Tilley: Founder and CEO, Beautiful Space 
   --    Mikuláš Peksa: MEP, European Parliament 

-- Dr David Erritzoe: Clinical Senior Lecturer & Consultant Psychiatrist, Imperial College London

   --    Tadeusz Hawrot: Founder And Executive Director, PAREA 
   --    Charlotte Nichols: Labour, Member Of UK Parliament 
   --    Amir Inamdar: Chief Medical Officer, Cybin Inc 
   --    George Mcbride: Chief Commercial Officer, Clerkenwell Health 

A full list of speakers can be found here .

This year's event is sponsored by Cybin, Shortwave Pharma, Negev Capital, Clerkenwell Health, Beautiful Space and FTI Consulting.

The PSYCH Symposium will take place on Thursday 6 July 2023, at The British Museum, London. Tickets are expected to sell out in advance of the event. For more information and to register, click here .

-ENDS-

Media inquiries : PsychSymposium@fticonsulting.com

The Directors of the Company accept responsibility for the contents of this announcement.

Enquiries:

Company:

Joseph Colliver: +44 20 3838 7621

William Potts: +44 20 3838 7621

info@psych.capital

https://psych.capital

Peterhouse Capital Limited:

Corporate Adviser:

Guy Miller / Narisha Ragoonanthun: + 44 (0) 20 7469 0930

Corporate Broker

Lucy Williams: +44 (0) 20 7469 0930

Duncan Vasey: +44 (0) 20 7220 9797 (Direct)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXNKDBNQBKDNAB

(END) Dow Jones Newswires

June 22, 2023 02:00 ET (06:00 GMT)

Shortwave Life Sciences (AQSE:PSY)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024

Shortwave Life Sciences (AQSE:PSY)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024